论文部分内容阅读
摘 要：［目的］ 探讨miRNAs在多发性骨髓瘤（multiple myeloma，MM）的临床价值。［方法］ 选择2014年1月至2016年1月于宝鸡市中医医院收治的多发性骨髓瘤患者50例，分别取其化疗前后的血清作为病例组，另选择同期体检的50名健康志愿者血清作为对照组。分别检测受试者血清以及病例组患者化疗前后血清中miRNAs的表达含量。［结果］ 病例组患者的miRNA-21和miRNA-29的表达水平显著性高于对照组（P<0.05），miRNA-15a以及miRNA-16等含量显著性低于对照组（P<0.05）。MM患者经化疗后，血清miRNA-21以及miRNA-29显著性降低（P<0.05），miRNA-15a和miRNA16的含量显著性升高（P<0.05），且化疗疗效有效的患者血清中相应miRNA指标变化水平较化疗疗效无效患者明显（P<0.05）。［结论］ miRNAs可能参与多发性骨髓瘤的发生发展，其异常表达情况可能为该疾病的预测和预后评价提供临床价值。
Abstract: [Objective] To investigate the clinical value of miRNAs in multiple myeloma (MM). [Methods] Fifty patients with multiple myeloma who were treated in Baoji TCM Hospital from January 2014 to January 2016 were enrolled. Serum before and after chemotherapy was selected as the case group. Another 50 healthy volunteers As a control group. The levels of miRNAs in sera of patients and serum of patients before and after chemotherapy were detected respectively. [Results] The expression of miRNA-21 and miRNA-29 in case group was significantly higher than that in control group (P <0.05). The contents of miRNA-15a and miRNA-16 were significantly lower than those in control group (P <0.05). Serum levels of miRNA-21 and miRNA-29 were significantly decreased (P <0.05) in MM patients after chemotherapy, and miRNA-15a and miRNA16 levels were significantly increased (P <0.05) in patients with MM, Indicators of change in patients with chemotherapy efficacy than patients with significant (P <0.05). [Conclusion] miRNAs may be involved in the development of multiple myeloma. The abnormal expression of miRNAs may provide clinical value for the prognosis and prediction of the disease.